ClinicaliQ Trial Snapshot
- Study to Assess the Efficacy, Safety, and Tolerability of NOC-110 in Adults With Refractory or Unexplained Chronic Cough — Active Not Recruiting • Phase II • NCT06504446.
- New inhaled powder drug tested against placebo for treating persistent cough that hasn't responded to standard treatments.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This is a phase 2b, randomized, double-blind, placebo-controlled study investigating the efficacy, safety, and tolerability of Taplucainium Inhalation Powder (NOC-110) once daily in adults with refractory or unexplained chronic cough. Conditions: Refractory or Unexplained Chronic Cough Interventions: NOC-110, Placebo Lead Sponsor: Nocion Therapeutics Planned Enrollment: 455 participants